- Home
- Publications
- Publication Search
- Publication Details
Title
Polo-like kinase and its inhibitors: Ready for the match to start?
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 90, Issue 11, Pages 1071-1076
Publisher
Wiley
Online
2015-08-21
DOI
10.1002/ajh.24177
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
- (2015) Na-Na Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Downregulation of Plk1 Expression By Receptor-Mediated Uptake of Antisense Oligonucleotide-Loaded Nanoparticles
- (2015) Birgit Spänkuch et al. NEOPLASIA
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
- (2014) C-C Lin et al. BRITISH JOURNAL OF CANCER
- Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.
- (2014) Ramesh K. Ramanathan et al. CANCER RESEARCH
- Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
- (2014) D. W. Bowles et al. CLINICAL CANCER RESEARCH
- Abstract B282: The PLK-4 inhibitor CFI-400945 reduces tumor growth in patient-derived pancreatic xenografts.
- (2014) I. Lohse et al. MOLECULAR CANCER THERAPEUTICS
- Abstract A182: Identifying biomarkers of sensitivity to polo-like kinase inhibitors (Plki) in non small cell lung cancer (NSCLC).
- (2014) R. Ferrarotto et al. MOLECULAR CANCER THERAPEUTICS
- PLK1expression and BI 2536 effects in childhood acute lymphoblastic leukemia
- (2014) J.C. Oliveira et al. PEDIATRIC BLOOD & CANCER
- Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells
- (2013) S. A. Hartsink-Segers et al. HAEMATOLOGICA
- The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
- (2013) Alessia Casolaro et al. PLoS One
- A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
- (2012) K Mross et al. BRITISH JOURNAL OF CANCER
- p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors
- (2012) Mourad Sanhaji et al. CELL CYCLE
- ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
- (2012) C. M. Chapman et al. CLINICAL CANCER RESEARCH
- PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
- (2012) G. Dasmahapatra et al. CLINICAL CANCER RESEARCH
- The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study
- (2012) Julie M. Vose et al. LEUKEMIA & LYMPHOMA
- Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
- (2012) Matthew J. Olnes et al. LEUKEMIA RESEARCH
- Abstract A207: Discovery of molecular mechanisms underlying cellular sensitivity to the PLK1 inhibitor TAK-960.
- (2012) K. Honda et al. MOLECULAR CANCER THERAPEUTICS
- MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
- (2012) J. Q. Shi et al. MOLECULAR CANCER THERAPEUTICS
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
- (2012) B. Valsasina et al. MOLECULAR CANCER THERAPEUTICS
- Azacitidine for the treatment of patients with acute myeloid leukemia
- (2011) Luca Maurillo et al. CANCER
- Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
- (2011) I. A. Oussenko et al. CANCER RESEARCH
- From Plk1 to Plk5
- (2011) Guillermo de Cárcer et al. CELL CYCLE
- Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
- (2011) D. Olmos et al. CLINICAL CANCER RESEARCH
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
- (2011) Mahesh Seetharam et al. LEUKEMIA RESEARCH
- TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
- (2011) Y. Hikichi et al. MOLECULAR CANCER THERAPEUTICS
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma
- (2010) Helen J. Stewart et al. EXPERIMENTAL HEMATOLOGY
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
- (2009) A. G. Renner et al. BLOOD
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Plk1-mediated Phosphorylation of Topors Regulates p53 Stability
- (2009) Xiaoming Yang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells
- (2009) A Prasad et al. ONCOGENE
- Polo-box domains confer target specificity to the Polo-like kinase family
- (2008) Barbara C.M. van de Weerdt et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development
- (2008) Tohru Takaki et al. CURRENT OPINION IN CELL BIOLOGY
- Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1
- (2008) Mark Petronczki et al. DEVELOPMENTAL CELL
- Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia
- (2008) Christine Didier et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Activation of Polo-like Kinase 3 by Hypoxic Stresses
- (2008) Ling Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
- (2008) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
- (2008) Klaus Mross et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started